30 September 2020 - CADTH initiated stakeholder consultations in June 2020 on proposals to align the procedure for its drug reimbursement review processes (i.e., pan-Canadian Oncology Drug Review [pCODR], Common Drug Review [CDR], and Interim Plasma Protein Product Review [PPP]). 

Individual or joint submissions were received from 80 organisations and companies that represent the pharmaceutical industry, patient and clinician groups, and government and non-profit agencies. All feedback has been documented and reviewed internally for action.

CADTH has carefully considered the feedback received during the consultation and is pleased to announce the new Procedures for CADTH Drug Reimbursement Reviews. These procedures will be effective for all applications targeting the April 2021 expert committee meetings.

Read CADTH Pharmaceutical Reviews Update